BioTech Navigator Investment Newsletter 1 00 News Page 7
7
BioTech Sage Report, January 2000
EPS Fiscal Year
1998 1999 (E)
Product
Indication
Clinical
Stage
(3.00) (.94)
ABX-IL8
Psoriasis
Phase I/II
(5.25) (1.42)
APC 2059
Psoriasis
Phase II
.90 (1.44)
LFA3TIP
Psoriasis
Phase IIa
-.34 -.28
BCX-34
Psoriasis
Phase II
-.55 -.82
carbohydrate-active enzyme
Psoriasis
Preclinical
.36 .38
SILKIS
Psoriasis
Phase III
-1.75 -2.93
PVAC compound
Severe scalp psoriasis
Phase I/II
-1.61 -1.16
OLUX
Psoriasis
PLA or NDA
.70 .92
Anti-CD11a
Psoriasis
Phase II
-1.17 NA
G202
Psoriasis
Phase I
.67 -1.16
ICM-3
Psoriasis
Phase I/II
.46 .95
Primatized Antibody
Psoriasis
Phase I/II
-.78 -.65
IR 502 therapeutic vaccine
Psoriasis
Phase II
-1.60 -1.71
Enbrel
Psoriasis
Phase III
.01 .25
ISIS 2302
Psoriasis
Preclinical
-2.92 -1.38
Oral Panretin
Psoriasis
Phase II
-.89 -.42
MDX-44
Psoriasis
Preclinical
.91 1.05
MEDI-507
Psoriasis
Phase I
-.48 -.44
Oral small molecule inhib of EGF and VEGF receptors Psoriasis Preclinical
1.31 1.80
SU5271
Psoriasis
Phase I
-.51 -.48
SMART Anti-CD3 Antibody
Zenapax
Psoriasis
Psoriasis
Phase I/II
Phase I/II
-.29 NA
Visudyne
Psoriasis
Phase II
1.18 1.41
Tenovil
Maxaciacitrol
Psoriasis
Psoriasis
Phase I
Phase I
-2.93 -2.63
2-CdAP
Psoriasis
Phase I/II
-1.16 -.87
hu1124
Psoriasis
Phase II
